Home
ImmunoGen

ImmunoGen Market Share Analysis for May 2026

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.

Health > Biotechnology and Pharmaceuticals

Domainimmunogen.com

Year Founded1980

Employees501 - 1000

Annual Revenue$200M - $500M

ImmunoGen

ImmunoGen (including company regionals)

immunogen.com

See more website traffic and engagement information

ImmunoGen Revenue up to May 2026 is 200M - 500M

revenue generated by ImmunoGen top domains

ImmunoGen top domains revenue over 3 years

Revenue for ImmunoGen top domains

immunogen.com200M - 500M

See more with Sales Intelligence

Total visits to ImmunoGen's top domains

Understand ImmunoGen market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in ImmunoGen's top domains

Analyze ImmunoGen engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on ImmunoGen's top domains

See how ImmunoGen keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

ImmunoGen top competitors by domain

Top similar sites in May 2026, ranked by their affinity

seattlegenetics.comCompany NameSeattle GeneticsEmployees1001 - 5000HQUnited StatesAnnual revenue--Total visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by ImmunoGen

These are the website technologies, by industry, used by ImmunoGen top domains

Advertising (9)

DoubleClick

Content Management System (4)

WordPress

Email Services (4)

Sendgrid

Widget (3)

Twemoji

More Technologies

13

See all

News & Signals from ImmunoGen

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsImmunoGen, Inc. launched Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone on Mar 1st '24.- On March 2024, ImmunoGen, Inc. announced a Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA).

NewsBaxter acquires ImmunoGen, Inc..Immuno AG was bought by US-based Baxter International, which has since been acquired by Takeda Pharmaceuticals.

NewsAbbVie Inc acquired ImmunoGen, Inc. on Feb 1st '24.ABBV acquired ImmunoGen, a biotechnology company focused on developing antibody-drug conjugate (ADC) therapeutics, in February.